Strategic expansion Momentum’s acquisition of OmicScouts and the recent CHIPP technology launch signal rapid upscale in capabilities and reach. This creates cross-sell opportunities to existing clients seeking integrated proteomics and mass spectrometry services, as well as入口 into European accounts through the strengthened SB.

Proteomics focus With formal proteomics services launched in 2023 and the OmicScouts integration, target biopharma clients increasingly needing proteomics data to complement MS-based drug discovery. Leverage this to position Momentum as a one-stop partner for proteomics-driven target profiling and downstream MS analyses.

High-throughput advantage Momentum’s heritage with RapidFire high-throughput MS and a 30+ instrument Mass Spec lab supports fast turnaround. This can appeal to clients with aggressive timelines and large screening campaigns, offering accelerated lead identification and characterization for degraders, PPI disruptors, molecular glues, and RNA binders.

SB and advisory strength Recent additions to the Scientific Advisory Board, including OmicScouts founders and notable bioscience leaders, enhance credibility for complex projects. Use this to approach mid- to late-stage programs that require expert guidance on assay development, chemoproteomics, and target profiling.

Global collaboration European operations expansion plus a CHIPP technology launch provide a narrative for multinational collaborations and scalable services. Target global biopharma clients with distributed R&D needs and emphasize seamless cross-border support and integrated MS/proteomics workflows.